Achieve Life Sciences (ACHV) Prices 476.19K Share Common Offering at $10.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
After-Hours Movers 08/03: (YRCW) (SEDG) (VRNS) Higher; (IMUX) (AIHS) (SPCE) Lower (more...)
August 3, 2020 6:14 PM EDTAfter-Hours Stock Movers:
YRC Worldwide (NASDAQ: YRCW) 45% HIGHER; reported Q2 EPS of ($1.09), $0.29 better than the analyst estimate of ($1.38). Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.01 billion.
SolarEdge Technologies (NASDAQ: SEDG) 12% HIGHER; reported Q2 EPS of $0.70, $0.01 better than the analyst estimate of $0.69. Revenue for the quarter came in at $331.9 million versus the consensus estimate of $319.42 million. SolarEdge Technologies sees Q3 2020 revenue of $325-350 million, versus the consensus of $330.8... More
Achieve Life Sciences (ACHV) Announces Proposed Common Share Offering
August 3, 2020 4:01 PM EDTAchieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its... More
Achieve Life Sciences (ACHV) Announces Patent Granted in U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
July 31, 2020 8:32 AM EDTAchieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (US 2020/0172544 A1) on novel analogs of... More
